/
CVM
$1.08-$0.03 (-2.70%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$19.4M
17M shares
52-week range
$0.89 – $13.48
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
XASE
CS
Price (6 mo)
Loading chart…
Change$-258.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $476.6K | $462.8K | $558.7K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $10.9K | $12.7K | $17.8K | $499.0K | $3.9M | $4.0M | $4.0M | $0 |
| Gross profit | $465.6K | $450.1K | $540.8K | −$499.0K | −$3.9M | −$4.0M | −$4.0M | $0 |
| Gross margin | 97.7% | 97.3% | 96.8% | — | — | — | — | — |
| R&D | $9.4M | $12.7M | $17.8M | $23.1M | $25.4M | $22.5M | $18.2M | $15.9M |
| Operating income | −$16.8M | −$20.2M | −$29.0M | −$36.2M | −$36.1M | −$31.5M | −$26.4M | −$24.8M |
| EBITDA | −$16.1M | −$19.7M | −$27.1M | −$34.7M | −$31.7M | −$27.6M | −$22.2M | −$20.9M |
| Net income | −$31.8M | −$24.7M | −$32.2M | −$39.2M | −$38.3M | −$32.4M | −$26.9M | −$25.4M |
| Net margin | -6680.7% | -5336.0% | -5767.9% | — | — | — | — | — |
| EPS (diluted) | -1685.10 | -21.60 | -26.40 | -28.80 | -26.70 | -21.90 | -13.50 | -6.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-4.16 | $-4.16–$-4.16 | 1 |
| 2027 | $19M | $-0.92 | $-0.92–$-0.92 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.21
Price
$1.08
Implied downside
-80%
Peer comparison
Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
www.cel-sci.com- Employees
- 44
- IPO / List date
- Dec 8, 1983
- HQ
- VIENNA, VA
Held by traders on TradeandTell
No one on the platform currently holds CVM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 35,890 | $115.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-05-20 | 1-for-30reverse |
| 2017-06-15 | 1-for-25reverse |
| 2013-09-25 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded CVM yet.
